The novel arylamidine T-2307 demonstratesin vitroandin vivoactivity against echinocandin-resistantCandida glabrata | Zendy

Nathan P. Wiederhold | Zendy; Laura K. Najvar | Zendy; Annette W. Fothergill | Zendy; Rosie Bocanegra | Zendy; Marcos Olivo | Zendy; Dora I. McCarthy | Zendy; Yoshiko Fukuda | Zendy; Junichi Mitsuyama | Zendy; Thomas F. Patterson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The novel arylamidine T-2307 demonstratesin vitroandin vivoactivity against echinocandin-resistantCandida glabrata

Author(s) -

Nathan P. Wiederhold,

Laura K. Najvar,

Annette W. Fothergill,

Rosie Bocanegra,

Marcos Olivo,

Dora I. McCarthy,

Yoshiko Fukuda,

Junichi Mitsuyama,

Thomas F. Patterson

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv398

Subject(s) - echinocandin , candida glabrata , caspofungin , in vivo , microbiology and biotechnology , in vitro , biology , pharmacology , medicine , antifungal , amphotericin b , fluconazole , biochemistry

Candida species are major causes of invasive mycoses in immunocompetent and immunocompromised hosts. Treatment options are limited in the setting of antifungal resistance and increased rates of echinocandin-resistant Candida glabrata have been reported. The novel arylamidine T-2307 demonstrates potent in vitro antifungal activity against Candida species. Our objective was to evaluate the in vitro and in vivo activity of T-2307 against resistant C. glabrata.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research